Synergistic activity of suramin with tumor necrosis factor alpha and doxorubicin on human prostate cancer cell lines.
Synergistic activity of suramin with tumor necrosis factor alpha and doxorubicin on human prostate cancer cell lines.
复制标题
苏拉明与肿瘤坏死因子 α 和阿霉素对人前列腺癌细胞系的协同活性。
DOI：
10.1093/jnci/82.14.1206
复制
发表时间：
1990
期刊：
影响因子：
--
通讯作者：
B. Sinha
中科院分区：
文献类型：
--
作者：
J. Fruehauf;C. Myers;B. Sinha
我们评估了苏拉明、阿霉素和肿瘤坏死因子α (tnf - α)对睾酮反应性人前列腺细胞系LNCaP和不依赖睾酮的人前列腺细胞系PC-3的作用。通过Chou和Talalay方法（剂量效应关系的定量分析）测试了这些药物联合使用的协同作用，以确定体外剂量是否在体内安全达到的水平下具有活性。在PC-3系中，阿霉素使苏拉明的作用增强了3倍，在LNCaP系中，阿霉素使苏拉明的作用增强了7倍。苏拉明- tnf - α和阿霉素- tnf - α联合用药对LNCaP均有协同作用。在临床常规达到的药物浓度下，注意到协同作用。本研究表明苏拉明、阿霉素和tnf - α是抗前列腺癌细胞系的活性药物，并且当它们联合使用时，活性可以增强。
We evaluated the action of suramin, doxorubicin, and tumor necrosis factor alpha (TNF-alpha) on the testosterone-responsive human prostate cell line LNCaP and on the testosterone-independent human prostate cell line PC-3. The synergistic action of these agents in combination was tested by the Chou and Talalay method (quantitative analysis of dose-effect relationships) to determine whether in vitro doses were active at levels safely achieved in vivo. The action of suramin was potentiated threefold by doxorubicin for the PC-3 line and seven-fold by doxorubicin for the LNCaP line. Both the suramin-TNF-alpha and the doxorubicin-TNF-alpha combinations showed synergistic action against the LNCaP line. Synergistic activity was noted at drug concentrations routinely achieved clinically. This study demonstrates that suramin, doxorubicin, and TNF-alpha are active agents against prostate cancer cell lines and that their activity can be enhanced when they are used in combination.